Efficacy of imiquimod 5% cream for persistent human papillomavirus in genital intraepithelial neoplasm

Taiwanese Journal of Obstetrics and Gynecology

Volumn 52, Issue 4, 2013, Pages 475-478

  Chen, Fang Ping ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cervical intraepithelial neoplasia; Gyne oncology; Human papillomavirus; Imiquimod 5 cream; Vaginal intraepithelial neoplasia

Indexed keywords

IMIQUIMOD;

ARTICLE; CANCER SURGERY; DISEASE SEVERITY; DRUG EFFICACY; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; RECURRENT DISEASE; TREATMENT DURATION; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA;

CERVICAL INTRAEPITHELIAL NEOPLASIA; GYNE-ONCOLOGY; HUMAN PAPILLOMAVIRUS; IMIQUIMOD 5% CREAM; VAGINAL INTRAEPITHELIAL NEOPLASIA;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINA; VAGINAL NEOPLASMS; VAGINAL SMEARS;

EID: 84892366889     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2013.10.004     Document Type: Article

References (25)

1. Paraskevaidis E., Kalantaridou S.N., Paschopoulos M., Zikopoulos K., Diakomanolis E., Dalkalitsis N., et al. Factors affecting outcome after incomplete excision of cervical intraepithelial neoplasia. Eur J Gynecol Oncol 2003, 24:541-543.
2. Milojkovic M. Residual and recurrent lesions after conization for cervical intraepithelial neoplasia grade 3. Int J Gynaecol Obstet 2002, 76:49-53.
3. Soutter W.P., Sasieni P., Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006, 118:2048-2055.
4. Flannelly G., Bolger B., Fawzi H., De Lopes A.B., Monaghan J.M. Follow up after LLETZ: could schedules be modified according to risk of recurrenceα. BJOG 2001, 108:1025-1030.
5. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papilloma virus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191:1808-1816.
6. Villa L.L. Human papillomaviruses and cervical cancer. Adv Cancer Res 1997, 71:321-341.
7. Chua K.L., Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 1997, 66:108-113.
8. Bodner K., Bodner-Adler B., Wierrani F., Kimberger O., Denk C., Grünberger W. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervixα A clinicopathological analysis. Anticancer Res 2002, 22:3733-3736.
9. Lacey C.J., Fairley I. Medical therapy of genital human papilloma virus-related disease. Int J STD AIDS 1995, 6:399-407.
10. Tyring S.K., Arany I., Stanley M.A., Tomai M.A., Miller R.L., Smith M.H., et al. A randomized controlled molecular study of condyloma acuminate clearance during treatment with imiquimod. J Infect Dis 1998, 178:551-555.
11. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., Tomai M.A. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999, 21:1-14.
12. Testerman T.L., Gerster J.F., Imbertson L.M., Reiter M.J., Miller R.L., Gibson S.J., et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995, 58:365-372.
13. Gibson S.J., Imbertson L.M., Wagner T.L., Testerman T.L., Reiter M.J., Miller R.L., et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995, 15:537-545.
14. van Seters M., Fons G., van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med 2002, 47:701-705.
15. Jayne C.J., Kaufman R.H. Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. J Reprod Med 2002, 47:395-398.
16. Todd R.W., Etherington I.J., Luesley D.M. The effect of 5% imiquimod cream on high-grade vulvar intraepithelial neoplasia. Gynecol Oncol 2002, 85:67-70.
17. Buck H.W., Guth K.J. Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream. J Low Genit Tract Dis 2003, 7:290-293.
18. Haidopoulos D., Diakomanolis E., Rodolakis A., Voulgaris Z., Vlachos G., Intsaklis A. Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vaginaα. Int J Gynecol Cancer 2005, 15:898-902.
19. Arany I., Tyring S.K., Brysk M.M., Stanley M.A., Tomai M.A., Miller R.L., et al. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifies (Imiquimod) in genital warts. Antimicrob Agents Chemother 2000, 44:1869-1873.
20. van Beurden M., ten Kate F.J., Smits H.L., Berkhout R.J., de Craen A.J., van der Vange N., et al. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer 1995, 75:2879-2884.
21. Diaz-Arrastia C., Arany I., Robazetti S.C., Dinh T.V., Gatalica Z., Tyring S.K., et al. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res 2001, 7:3031-3033.
22. van Seters M., van Beurden M., ten Kate F.J., Beckmann I., Ewing P.C., Eijkemans M.J., et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008, 358:1465-1473.
23. 2 laser vaporization in the treatment of cervical human papillomavirus infection in women with abnormal Papanicolaou smears. Gynecol Obstet Invest 1992, 33:172-176.
24. Travis L.B., Weinberg J.M., Krumholz B.A. Successful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplanted patient. Acta Derm Venerol 2002, 82:475-476.
25. Chua K.L., Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996, 77:121-127.